Circulating neprilysin hypothesis
Circulating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤
Lupón, Josep|| +10 more
openaire +1 more source
In Vivo Inhibition of Dipeptidyl Peptidase 4 and Neprilysin Activity Enables Measurement of GLP-1 Secretion in Male Rats. [PDF]
Galsgaard KD +4 more
europepmc +1 more source
Pharmacophore-Based Identification and Molecular Characterization of Potent Neprilysin Inhibitors: Biochemical and Therapeutic Implications for Cardiovascular Diseases. [PDF]
Kuo CT, Wu YC, Li JM, Ju TC, Tseng TS.
europepmc +1 more source
Retraction: The angiotensin receptor neprilysin inhibitor LCZ696 attenuates renal fibrosis via ASK1/JNK/p38 MAPK-mediated apoptosis in unilateral ureteral obstruction. [PDF]
PLOS One Editors.
europepmc +1 more source
Bleeding Disorder, A Newly Recognized Adverse Event Following Sacubitril/Valsartan Therapy. [PDF]
Al-Omari YW +3 more
europepmc +1 more source
Short-term renal and cardiac outcomes of combined ARNI and SGLT2 therapy in AHF patients: a prospective single-arm interventional study. [PDF]
Zhang M, Huang Z, Wang C, Xu Y.
europepmc +1 more source
Bibliometric analysis of sacubitril/valsartan in the management of chronic kidney disease (2013-2025). [PDF]
Liu P, He X, Luo X, Xie S, Li Y, Su B.
europepmc +1 more source
Japanese Nationwide Survey of New Heart Failure Drug Prescriptions by Pediatric Cardiologists. [PDF]
Muneuchi J, Collaborators.
europepmc +1 more source

